Oral vaccine delivery - New strategies and technologies

Current Drug Delivery

Volumn 6, Issue 4, 2009, Pages 347-358

  Simerska, Pavla ^a   Moyle, Peter M ^a   Olive, Colleen ^b   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Oral delivery; Technology; Vaccines

Indexed keywords

AD4; AD7; ALVAKOL; AMIVAX; ATIT AP; BCG VACCINE; BIOSTIM; CHOLERA VACCINE; DIPHTHERIA TOXIN; DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; FREUND ADJUVANT; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMUCOR; INACTIVATED VACCINE; INFLUENZA VACCINE; KANVAKOL; LIVE VACCINE; LUIVAC; MALARIA VACCINE; MEASLES VACCINE; MUTACHOL; NANOPARTICLE; O111; ORAL POLIOMYELITIS VACCINE; PASPAT; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; PERTUSSIS VACCINE; PLASMID DNA; PROTEIN DERIVATIVE; RABIES VACCINE; RABORAL V RG; RECOMBINANT VACCINE; RESPIVAX; RIBOMUNYL; ROTAVIRUS VACCINE; SABINS; SAD; SAG2; SMALLPOX VACCINE; STREPTOCOCCUS VACCINE; TEOVAC; TETANUS TOXOID; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URVAKOL; V 1 IMMUNITOR; VACCINE; VAXIHALER FLU; WART VIRUS VACCINE; WC RBS;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; DNA IMMUNIZATION; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TRANSPORT; GASTROINTESTINAL TRACT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; INTESTINE WALL; MUCOSAL IMMUNITY; NONHUMAN; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; VIRUS PARTICLE;

ADMINISTRATION, ORAL; ANIMALS; DRUG DESIGN; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL ABSORPTION; PEPTIDES; PROTEINS; TECHNOLOGY, PHARMACEUTICAL; VACCINES;

EID: 68949116145     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720109789000537     Document Type: Review

References (144)

1. Silin, D. S.; Lyubomska, O. V.; Jirathitikal, V.; Bourinbaiar, A. S. Oral vaccination: where we are? Expert Opin. Drug Deliv., 2007, 4, 323-340.
2. Mestecky, J.; Russell, M. W.; Elson, C. O. Perspectives on mucosal vaccines: Is mucosal tolerance a barrier? J. Immunol., 2007, 179, 5633-5638.
3. McNeela, E. A.; Mills, K. H. G. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Deliv. Rev., 2001, 51, 43-54.
4. Aziz, M. A.; Midha, S.; Waheed, S. M.; Bhatnagar, R. Oral vaccines: new needs, new possibilities. Bioessays, 2007, 29, 591-604. (Pubitemid 46903947)
5. Russell-Jones, G. J. Oral vaccine delivery. J. Control. Release, 2000, 65, 49-54.
6. Shaji, J.; Patole, V. Protein and Peptide Drug Delivery: Oral Approaches. Indian J. Pharm. Sci., 2008, 70, 269-277.
7. Wagner, B.; Earn, D. Circulating Vaccine Derived Polio Viruses and their Impact on Global Polio Eradication. B. Math. Biol., 2008, 70, 253-280.
8. Sutter, R. W.; Prevots, D. R.; Cochi, S. L. Poliovirus vaccines - Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr. Clin. North Am., 2000, 47, 287-308.
9. Longini, I. M. J.; Nizam, A.; Ali, M.; Yunus, M.; Shenvi, N.; Clemens, J.D. Controlling endemic cholera with oral vaccines. PLoS Med., 2007, 4, e336.
10. Roland, K. L.; Cloninger, C.; Kochi, S. K.; Thomas, L. J.; Tinge, S. A.; Rouskey, C.; Killeen, K. P. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine, 2007, 25, 8574-8584.
11. Avtushenko, S. S.; Sorokin, E. M.; Zoschenkova, N. Y.; Naichin, A. N. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization. J. Biotechnol., 1996, 44, 21-28.
12. Lazzell, V.; Waldman, R. H.; Rose, C.; Khakoo, R.; Jacknowitz, A.; Howard, S. Immunization against Influenza in Humans Using an Oral Enteric-Coated Killed Virus-Vaccine. J. Biol. Standard., 1984, 12, 315-321.
13. Dutta, A. Epidemiology of poliomyelitis-Options and update. Vaccine, 2008, 26, 5767-5773.
14. Bonnet, M. C.; Dutta, A. World wide experience with inactivated poliovirus vaccine. Vaccine, 2008, 26, 4978-4983.
15. Singh, S. K. Oral polio vaccines: a matter for debate. Future Microbiol., 2008, 3, 383-385.
16. Nygren, E.; HoIrngren, J.; Attridge, S. R. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine, 2008, 26, 6784-6790.
17. Holmgren, J.; Clemens, J. D., Cholera immunity and cholera vaccination. Springer: 2008; pp. 173-194.
18. Germanier, R.; Furer, E. Isolation and characterization of Gal-E mutant Ty 21A of Salmonella-typhi-candidate strain for a live, oral typhoid vaccine. J. Infect. Dis., 1975, 131, 553-558.
19. Levine, M. M.; Ferreccio, C.; Black, R. E.; Lagos, R.; San Martin, O.; Blackwelder, W. C. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin. Infect. Dis., 2007, 45 (Suppl. 1) S24-S28.
20. Fraser, A.; Goldberg, E.; Acosta, C. J.; Paul, M.; Leibovici, L. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev., 2007, 48.
21. Ward, R. L.; Bernstein, D. I. Rotarix: A Rotavirus Vaccine for the World. Clin. Infect. Dis., 2009, 48, 222-228.
22. Chandran, A.; Santosham, M. RotaTeq (TM): a three-dose oral pentavalent reassortant rotavirus vaccine. Expert Rev. Vaccines, 2008, 7, 1475-1480.
23. Foster, R. H.; Wagstaff, A. J. Tetravalent human-rhesus reassortant rotavirus vaccine - A review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis. Biodrugs, 1998, 9, 155-178.
24. Tucker, S. N.; Tingley, D. W.; Scallan, C. D. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev. Vaccines, 2008, 7, 25-31.
25. Piedra, P. A.; Poveda, G. A.; Ramsey, B.; McCoy, K.; Hiatt, P. W. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors. Pediatrics, 1998, 101, 1013-1019.
26. Melnikov, S. A.; Podkuiko, V. N.; Khamitov, R. A.; Maksimov, V. A.; Markov, V. I.; Vorobyev, A. A.; Shagarov, E. E.; Shulga, S. V.; Chernikova, N. K.; Kharchenko, T. N.; Rodionova, M. P. Clinical studies of vaccine TEOVac under the conditions of remote revaccination. Zhurnal Mikrobiol. Epidem. Immunobiol., 2005, 29-33.
27. Kilari, S.; Mebatsion, T.; Visser, N. Canine rabies control - Oral Rabies Vaccines (ORV) as a complementary tool to parental immunization. J. Commonwealth Veterinary Assoc., 2008, 24, 18-19.
28. Thomas, J. K.; Noppenberger, J. Avian influenza: A review. Am. J. Health-Syst. Pharm., 2007, 64, 149-165.
29. Bourinbaiar, A. S., AIDS vaccines and related topics. Research Signpost: Trivandrum India, 2004; p 239.
30. Cazzola, M.; Rogliani, P.; Curradi, G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. Respir. Med., 2008, 102, 321-327.
31. Cripps, A. W. Mucosal immunization for bacterial respiratory infections. Hum. Vaccines, 2008, 4, 396-399.
32. Bourinbaiar, A. S.; Metadilogkul, O.; Jirathitikal, V. Mucosal AIDS vaccines. Viral. Immunol., 2003, 16, 427-445.
33. Silin, D. S.; Liao, C.-W.; Lyubomska, O. V.; Weng, C.-N. Immunity development following oral vaccination against Actinobacillus pleuropneumoniae in a mouse model. Int. J. Biotechnol., 2007, 9, 381-390.
34. Dluholucky, S.; Siragy, P.; Dolezel, P.; Svac, J.; Bolgac, A. Antimicrobial activity of colostrum after administering killed Escherichia-Coli 0111 vaccine orally to expectant mothers. Arch. Dis. Childhood, 1980, 55, 458-460.
35. Goetsch, L. N.; Gonzalez, A.; Plotnicky-Gilquin, H.; Haeuw, J. F.; Aubry, J. P.; Beck, A.; Bonnefoy, J. Y.; Corvia, N. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein a derived from Klebsiella pneumoniae. Infect. Immun., 2001, 69, 6434-6444.
36. Van Immerseel, F.; Methner, U.; Rychlik, I.; Nagy, B.; Velge, P.; Martin, G.; Foster, N.; Ducatelle, R.; Barrow, P. A. Vaccination and early protection against non-host-specific Salmonella serotypes in poultry: exploitation of innate immunity and microbial activity. Epidemiol. Infect., 2005, 133, 959-978.
37. Portales, P.; Clot, J. Immuno stimulants revisited - Focus on the pharmacology of ribomunyl((R)). Biodrugs, 2006, 20, 81-84.
38. Benevolo-de-Andrade, T. C.; Monteiro-Maia, R.; Cosgrove, C.; Castello-Branco, L. R. R. BCG Moreau Rio de Janeiro - An oral vaccine against tuberculosis - Review. Mem. Inst. Oswaldo Cruz, 2005, 100, 459-465.
39. Vipond, J.; Cross, M. L.; Lambeth, M. R.; Clark, S.; Aldwell, F. E.; Williams, A. Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection. Microbes Infect., 2008, 10, 1577-1581.
40. Barr, E.; Sings, H. L. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine, 2008, 26, 6244-6257.
41. Pinzon-Charry, A. Edible malaria vaccines that bear fruit. Med. Hypotheses, 2007, 68, 1180-1181. (Pubitemid 46274058)
42. Wang, L.; Webster, D. E.; Campbell, A. E.; Dry, I. B.; Wesselingh, S. L.; Coppel, R. L. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int. J. Parasitol., 2008, 38, 103-110.
43. Katz, D. E.; DeLorimier, A. J.; Wolf, M. K.; Hall, E. R.; Cassels, F. J.; van Hamont, J. E.; Newcomer, R. L.; Davachi, M. A.; Taylor, D. N.; McQueen, C. E. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine, 2003, 21, 341-346.
44. Webster, D. E.; Thomas, M. C.; Strugnell, R. A.; Dry, I. B.; Wesselingh, S. L. Appetising solutions: an edible vaccine for measles. Med. J. Aust., 2002, 176, 434-437.
45. Coates, A. L.; Tipples, G.; Leung, K.; Gray, M.; Louca, E.; Measles, W. H. O. P. D. G. How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine, 2006, 24, 1578-1585.
46. Lagranderie, M.; Chavarot, P.; Balazuc, A. M.; Marchal, G. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine, 2000, 18, 1186-1195.
47. Sory, M. P.; Hermand, P.; Vaerman, J. P.; Cornelis, G. R. Oral immunization of mice with a live recombinant Yersinia- Enterocolitica O-9 strain that produces the cholera toxin-B subunit. Infect. Immun., 1990, 58, 2420-2428.
48. Seegers, J. F. M. L. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol., 2002, 20, 508-515.
49. Sharon, M.; Nir, P.; Lior, K.; David, B. N.; Tomer, I.; Paula, S.; Reuven, L.; Shlomo, L. Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine, 2007, 25, 7743-7753. (Pubitemid 47588531)
50. Zimmerman, R. K.; Spann, S. J. Poliovirus vaccine options. Am. Fam. Physician, 1999, 59, 113-118.
51. Zhang, Y.-d.; Lu, X.-l.; Li, N.-f. The prospective preventative HIV vaccine based on modified poliovirus. Med. Hypotheses, 2007, 68, 1258-1261.
52. Santos, N.; Hoshino, Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol., 2005, 15, 29-56. (Pubitemid 40070041)
53. Kanesaki, T.; Murphy, B. R.; Ogra, P. L. In Efectiveness of enteric immunization in the development of secretory IgA response and outcome of infection with respiratory syncytial virus., Tokyo, Japan, Jul 22-27; Tsuchiya, M.; Nagura, H.; Hibi, T.; Moro, I., Eds. Elsevier Science Publ B V: Tokyo, Japan, 1990; pp. 617-620.
54. Ogra, P. L.; Faden, H.; Welliver, R. C. Vaccination strategies for mucosal immune responses (vol 14, pg 430, 2001). Clin. Microbiol. Rev., 2001, 14, 641-641
55. Lubeck, M. D.; Davis, A. R.; Chengalvala, M.; Natuk, R. J.; Morin, J. E.; Molnar-Kimber, K.; Mason, B. B.; Bhat, B. M.; Mizutani, S.; Hung, P. P.; Purcell, R. H. Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus. Proc. Natl. Acad. Sci. USA, 1989, 86, 6763-6767.
56. Zhou, Z. W.; Xia, H. M.; Hu, X. C.; Huang, Y.; Li, Y. W.; Li, L.; Ma, C. L.; Chen, X. X.; Hu, F. Y.; Xu, J.; Lu, F. L.; Wu, Z. D.; Yu, X. B. Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis. Vaccine, 2008, 26, 1817-1825.
57. Yigang, X. U.; Yijing, L. I. Construction of recombinant Lactobacillus casei efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization. Immunology, 2008, 124, 68-75.
58. Oggioni, M. R.; Manganelli, R.; Contorni, M.; Tommasino, M.; Pozzi, G. Immunization of mice by oral colonization with live recombinant commensal Streptococci. Vaccine, 1995, 13, 775-779.
59. Alpar, H. O.; Bowen, J. C.; Brown, M. R. W. Efectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int. J. Pharm., 1992, 88, 335-344.
60. Rydell, N.; Stertman, L.; Stalenheim, G.; Sjoholm, I. Use of an oral diphtheria vaccine in human. Vaccine, 2006, 24, 5928-5930. (Pubitemid 44080357)
61. Pichichero, M. E.; Rennels, M. B.; Edwards, K. M.; Blatter, M. M.; Marshall, G. S.; Bologa, M.; Wang, E.; Mills, E. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA-J. Am. Med. Assoc., 2005, 293, 3003-3011. (Pubitemid 40965070)
62. Noad, R.; Roy, P. Virus-like particles as immunogens. Trends Microbiol., 2003, 11, 438-444.
63. Niikura, M.; Takamura, S.; Kim, G.; Kawai, S.; Saijo, M.; Morikawa, S.; Kurane, I.; Li, T.-C.; Takeda, N.; Yasutomi, Y. Chimeric Recombinant Hepatitis E Virus-like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes. Virology, 2002, 293, 273-280. (Pubitemid 34928848)
64. Da Silva, D. M.; Velders, M. P.; Nieland, J. D.; Schiller, J. T.; Nickoloff, B. J.; Kast, W. M. Physical interaction of human papillomavirus virus-like particles with immune cells. Int. Immunol., 2001, 13, 633-641. (Pubitemid 32427866)
65. Guerrero, R. A.; Ball, J. M.; Krater, S. S.; Pacheco, S. E.; Clements, J. D.; Estes, M. K. Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses. J. Virol., 2001, 75, 9713-9722.
66. Li, T. C.; Takeda, N.; Miyamura, T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine, 2001, 19, 3476-3484. (Pubitemid 32710299)
67. McCluskie, M. J.; Weeratna, R. D.; Krieg, A. M.; Davis, H. L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine, 2000, 19, 950-957.
68. Krieg, A. M. From A to Z on CpG. Trends Immunol., 2002, 23, 64-65.
69. Tian, J.; Yu, J.; Sun, X. Chitosan microspheres as candidate plasmid vaccine carrier for oral immunisation of Japanese flounder (Paralichthys olivaceus). Vet. Immunol. Immunopathol., 2008, 126, 220-229.
70. Kuklin, N.; Daheshia, M.; Karem, K.; Manickan, E.; Rouse, B. T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol., 1997, 71, 3138-3145.
71. Robinson, H. L. HIV/AIDS vaccines: 2007. Clin. Pharm. Therap., 2007, 82, 686-693.
72. Pertmer, T. M.; Oran, A. E.; Moser, J. M.; Madorin, C. A.; Robinson, H. L. DNA Vaccines for Influenza Virus: Differential Effects of Maternal Antibody on Immune Responses to Hemagglutinin and Nucleoprotein. J. Virol., 2000, 74, 7787-7793.
73. Haq, T. A.; Mason, H. S.; Clements, J. D.; Arntzen, C. J. Oral Immunization with a Recombinant Bacterial-Antigen Produced in Transgenic Plants. Science, 1995, 268, 714-716.
74. Sonaje, K.; Lin, Y.-H.; Juang, J.-H.; Wey, S.-P.; Chen, C.-T.; Sung, H.-W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials, 2009, 30, 2329-2339.
75. Pinto Reis, C.; Neufeld, R. J.; Ribeiro, A. J.; Veiga, F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomed. Nanotech. Biol. Med., 2006, 2, 53-65.
76. Garinot, M.; Fievez, V.; Pourcelle, V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jerome, C.; Marchand- Brynaert, J.; Schneider, Y. J.; Preat, V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120, 195-204.
77. Singh, R.; Singh, S.; Lillard, J. W. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci., 2008, 97, 2497-2523.
78. Rajesh Kumar, S.; Ishaq Ahmed, V. P.; Parameswaran, V.; Sudhakaran, R.; Sarath Babu, V.; Sahul Hameed, A. S. Potential use of chitosan nanoparticles for oral delivery of DNA vaccine in Asian sea bass (Lates calcarifer) to protect from Vibrio (Listonella) anguillarum. Fish Shelfish Immunol., 2008, 25, 47-56.
79. Eldridge, J. H.; Staas, J. K.; Meulbroek, J. A.; Tice, T. R.; Gilley, R. M. Biodegradable and biocompatible poly(DL-lactide-coglycolide) microspheres as an adjuvant for Staphylococcal enterotoxin-B toxoid which enhances the level of toxin-neutralizing antibodies. Inf. Immunity, 1991, 59, 2978-2986.
80. Jones, D. H.; McBride, B. W.; Thornton, C.; Ohagan, D. T.; Robinson, A.; Farrar, G. H. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B-pertussis respiratory infection. Infect. Immun., 1996, 64, 489-494.
81. Chattaraj, S. C.; Rathinavelu, A.; Das, S. K. Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. J. Control. Release, 1999, 58, 223-232.
82. Carcaboso, A. M.; Hernandez, R. M.; Igartua, M.; Gascon, A. R.; Rosas, J. E.; Patarroyo, M. E.; Pedraz, J. L. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int. J. Pharm., 2003, 260, 273-282.
83. Rogers, J. A.; Anderson, K. E. The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 1998, 15, 421-480.
84. Ann Clark, M.; Blair, H.; Liang, L.; Brey, R. N.; Brayden, D.; Hirst, B. H. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine, 2001, 20, 208-217.
85. Guzman, C. A.; Molinari, G.; Fountain, M. W.; Rohde, M.; Timmis, K. N.; Walker, M. J. Antibody-responses in the serum and respiratory-tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid. Infect. Immun., 1993, 61, 573-579.
86. Childers, N. K.; Tong, G.; Li, F.; Dasanayake, A. P.; Kirk, K.; Michalek, S. M. Humans immunized with Streptococcus mutans antigens by mucosal routes. J. Dental Res., 2002, 81, 48-52.
87. Therien, H. M.; Lair, D.; Shahum, E. Liposomal vaccine - influence of antigen association on the kinetics of the humoral response. Vaccine, 1990, 8, 558-562.
88. Babiuk, L. A. Broadening the approaches to developing more effective vaccines. Vaccine, 1999, 17, 1587-1595.
89. Wiesmüller, K.-H.; Fleckenstein, B.; Jung, G. Peptide vaccines and peptide libraries. Biol. Chem., 2001, 382, 571-579.
90. BenMohamed, L.; Wechsler, S. L.; Nesburn, A. B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis., 2002, 2, 425-431.
91. Purcell, A. W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov., 2007, 6, 404-414.
92. Mattingly, J. A.; Waksman, B. H. Immunological suppression after oral-administration of antigen. 1. Specific suppressor cells formed in rat peyers patches after oral-administration of sheep erythrocytes and their systemic migration. J. Immunol., 1978, 121, 1878-1883.
93. Shahin, R. D.; Amsbaugh, D. F.; Leef, M. F. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect. Immun., 1992, 60, 1482-1488.
94. Mirchamsy, H.; Hamedi, M.; Fateh, G.; Sassani, A. Oral Immunization against Diphtheria and Tetanus Infections by Fluid Diphtheria and Tetanus Toxoids. Vaccine, 1994, 12, 1167-1172. (Pubitemid 24293235)
95. Durier, C.; Launay, O.; Meiffrédy, V.; Saïdi, Y.; Salmon, D.; Lévy, Y.; Guillet, J. G.; Pialoux, G.; Aboulker, J. P. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. Aids, 2006, 20, 1039-1049.
96. Seth, A.; Yasutomi, Y.; Jacoby, H.; Callery, J. C.; Kaminsky, S. M.; Koff, W. C.; Nixon, D. F.; Letvin, N. L. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res. Hum. Retroviruses, 2000, 16, 337-343.
97. Steller, M. A.; Gurski, K. J.; Murakami, M.; Daniel, R. W.; Shah, K. V.; Celis, E.; Sette, A.; Trimble, E. L.; Park, R. C.; Marincola, F. M. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res., 1998, 4, 2103-2109.
98. Olive, C.; Sun, H. K.; Ho, M.-F.; Dyer, J.; Horváth, A.; Toth, I.; Good, M. F. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J. Infect. Dis., 2006, 194, 316-324.
99. Batzloff, M. R.; Hartas, J.; Zeng, W.; Jackson, D. C.; Good, M. F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal Peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group a streptococcus challenge and reduces throat colonization. J. Infect. Dis., 2006, 194, 325-330.
100. Deliyannis, G.; Kedzierska, K.; Lau, Y. F.; Zeng, W.; Turner, S. J.; Jackson, D. C.; Brown, L. E. Intranasal lipopeptide primes lungresident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur. J. Immunol., 2006, 36, 770-778.
101. BenMohamed, L.; Belkaid, Y.; Loing, E.; Brahimi, K.; Gras- Masse, H.; Druilhe, P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol., 2002, 32, 2274-2281.
102. BenMohamed, L.; Krishnan, R.; Auge, C.; Primus, J. F.; Diamond, D. J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology, 2002, 106, 113-121. (Pubitemid 34437884)
103. Mittenbuhler, K.; Baier, W.; van der Esche, U.; Heinevetter, L.; Wiesmuller, K.-H.; Jung, G.; Weckesser, J.; Bessler, W. G.; Hoffmann, P. Lipopeptides as efficient novel immunogens and adjuvants in parenteral and oral immunization. Cur. Topics Pept. Protein Res., 1997, 2, 125-135.
104. Nardelli, B.; Haser, P. B.; Tam, J. P. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine, 1994, 12, 1335-1339.
105. Deprez, B.; Sauzet, J.-P.; Boutillon, C.; Martinon, F.; Tartar, A.; Sergheraert, C.; Guillet, J.-G.; Gomard, E.; Gras-Masse, H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine, 1996, 14, 375-382. (Pubitemid 26153332)
106. Klinguer, C.; David, D.; Kouach, M.; Wieruszeski, J. M.; Tartar, A.; Marzin, D.; Lévy, J. P.; Gras-Masse, H. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine, 1999, 18, 259-267. (Pubitemid 29443999)
107. + T lymphocyte activation. Eur. J. Immunol., 2000, 30, 3256-3265.
108. Gahéry-Ségard, H.; Pialoux, G.; Charmeteau, B.; Sermet, S.; Poncelet, H.; Raux, M.; Tartar, A.; Lévy, J. P.; Gras-Masse, H.; Guillet, J.-G. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol., 2000, 74, 1694-1703.
109. Pialoux, G.; Gahéry-Ségard, H.; Sermet, S.; Poncelet, H.; Fournier, S.; Gérard, L.; Tartar, A.; Gras-Masse, H.; Lévy, J. P.; Guillet, J. G. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS, 2001, 15, 1239-1240. (Pubitemid 32592356)
110. +-T-cell epitopes recognized. J. Virol., 2003, 77, 11220-11231.
111. Lévy, Y.; Gahéry-Ségard, H.; Durier, C.; Lascaux, A. S.; Goujard, C.; Meiffrédy, V.; Rouzioux, C.; El Habib, R.; Beumont-Mauviel, M.; Guillet, J.-G.; Delfraissy, J.-F.; Aboulker, J.-P. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS, 2005, 19, 279-286. (Pubitemid 40396559)
112. + T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses, 2006, 22, 684-694.
113. BenMohamed, L.; Gras-Masse, H.; Tartar, A.; Daubersies, P.; Brahimi, K.; Bossus, M.; Thomas, A.; Druilhe, P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol., 1997, 27, 1242-1253. (Pubitemid 27197230)
114. Benmohamed, L.; Thomas, A.; Bossus, M.; Brahimi, K.; Wubben, J.; Gras-Masse, H.; Druilhe, P. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine, 2000, 18, 2843-2855. (Pubitemid 30254472)
115. BenMohamed, L.; Thomas, A.; Druilhe, P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liverstage peptides and lipopeptides. Infect. Immun., 2004, 72, 4376-4384. (Pubitemid 38989293)
116. Persing, D. H.; McGowan, P.; Evans, J. T.; Cluff, C.; Mossman, S.; Johnson, D.; Baldridge, J. R., Toll-like receptor 4 agonists as vaccine adjuvants. In Immunopotentiators in modern vaccines, Virgil, E. J. C.; O'Hagan, D. T., Eds. Elsevier Academic Press: Burlington, MA, 2006; pp. 93-108.
117. Ouellette, A. J.; Satchell, D. P.; Hsieh, M. M.; Hagen, S. J.; Selsted, M. E. Characterization of luminal paneth cell alpha-defensins in mouse small intestine. Attenuated antimicrobial activities of peptides with truncated amino termini. J. Biol. Chem., 2000, 275, 33969-33973.
118. Baldridge, J. R.; McGowan, P.; Evans, J. T.; Cluff, C.; Mossman, S.; Johnson, D.; Persing, D. H. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Exp. Opin. Biol. Therap., 2004, 4, 1129-1138.
119. Johnson, A. G., Adjuvant action of bacterial endotoxins on the primary antibody response. In Bacterial endotoxins: Proceedings of a symposium held at the Institute of Microbiology of Rutgers, the State University with support from the National Science Foundation, Landy, M.; Braun, W., Eds. Rutgers University Press: New Brunswick, NJ, 1964; pp. 252-262.
120. Ulrich, J. T.; Myers, K. R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol., 1995, 6, 495-524.
121. Doherty, T. M.; Olsen, A. W.; van Pinxteren, L.; Andersen, P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun., 2002, 70, 3111-3121. (Pubitemid 34564174)
122. Cross, M. L.; Lambeth, M. R.; Aldwell, F. E. Murine cytokine responses following multiple oral immunizations using lipid-formulated mycobacterial antigens. Immunol. Cell Biol., 2007, 86, 214-217.
123. Moyle, P. M.; Horvath, A.; Olive, C.; Good, M. F.; Toth, I. Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection. Lett. Pept. Sci., 2003, 10, 605-613. (Pubitemid 40379053)
124. Toth, I.; Danton, M.; Flinn, N.; Gibbons, W. A. A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilizing lipidic amino acids. Tetrahedron Lett., 1993, 34, 3925-3928.
125. McGeary, R. P.; Jablonkai, I.; Toth, I. Towards synthetic vaccines built on carbohydrate cores. Lett. Pept. Sci., 2002, 8, 273-276.
126. McGeary, R. P.; Jablonkai, I.; Toth, I. Carbohydrate-based templates for synthetic vaccine and drug delivery. Tetrahedron, 2001, 57, 8733-8742. (Pubitemid 32947080)
127. Simerska, P.; Abdel-Aal., A.B.M.; Fujita, Y.; Batzloff, M.R.; Good, M.F.; Toth, I. Synthesis and in vivo studies of carbohydrate-based vaccines against group A Streptococcus. Pept. Sci., 2008, 90, 611-616.
128. Moyle, P. M.; Olive, C.; Ho, M. F.; Pandey, M.; Dyer, J.; Suhrbier, A.; Fujita, Y.; Toth, I. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J. Med. Chem., 2007, 50, 4721-4727. (Pubitemid 47463245)
129. Roy, R. New trends in carbohydrate-based vaccines. Drug Discov. Today Technol., 2004, 1, 327-336.
130. Verez-Bencomo, V.; Fernandez-Santana, V.; Hardy, E.; Toledo, M. E.; Rodriguez, M. C.; Heynngnezz, L.; Rodriguez, A.; Baly, A.; Herrera, L.; Izquierdo, M.; Villar, A.; Valdes, Y.; Cosme, K.; Deler, M. L.; Montane, M.; Garcia, E.; Ramos, A.; Aguilar, A.; Medina, E.; Torano, G.; Sosa, I.; Hernandez, I.; Martinez, R.; Muzachio, A.; Carmenates, A.; Costa, L.; Cardoso, F.; Campa, C.; Diaz, M.; Roy, R. A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b. Science, 2004, 305, 522-525. (Pubitemid 38971343)
131. Koeller, K. M.; Wong, C. H. Synthesis of complex carbohydrates and glycoconjugates: enzyme-based and programmable one-pot strategies. Chem. Rev., 2000, 100, 4465-4494.
132. Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Automated solid-phase synthesis of oligosaccharides automated solid-phase synthesis of oligosaccharides. Science, 2001, 291, 1523.
133. Simerska, P.; Abdel-Aal, A. B. M.; Fujita, Y.; Moyle, P. M.; McGeary, R. P.; Batzloff, M. R.; Olive, C.; Good, M. F.; Toth, I. Development of a liposaccharide-based delivery system and its application to the design of group a streptococcal vaccines. J. Med. Chem., 2008, 51, 1447-1452.
134. Brewer, J. M. (How) do aluminium adjuvants work? Immunol. Lett., 2006, 102, 10-15.
135. Chapel, H. M.; August, P. J. Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clin. Exp. Immunol., 1976, 24, 538-541.
136. Aguilar, J. C.; Rodriguez, E. G. Vaccine adjuvants revisited. Vaccine, 2007, 25, 3752-3762.
137. Berner, V. K.; Sura, M. E.; Hunter, K. W. Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations. Appl. Microbiol. Biotechnol., 2008, 80, 1053-1061.
138. Purcell, A. W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov., 2007, 6, 404-414. (Pubitemid 46696551)
139. Mahato, R. I.; Narang, A. S.; Thoma, L.; Miller, D. D. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 2003, 20, 153-214. (Pubitemid 37237279)
140. Whitehead, K.; Karr, N.; Mitragotri, S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res., 2008, 25, 1782-1788.
141. Maloy, K. J.; Donachie, A. M.; Ohagan, D. T.; Mowat, A. M. Induction of mucosal and systemic immune-responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology, 1994, 81, 661-667.
142. Bernkop-Schnürch, A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release, 1998, 52, 1-16. (Pubitemid 28123168)
143. Toorisaka, E.; Hashida, M.; Kamiya, N.; Ono, H.; Kokazu, Y.; Goto, M. An enteric-coated dry emulsion formulation for oral insulin delivery. J. Control. Release, 2005, 107, 91-96. (Pubitemid 41253705)
144. Lowman, A. M.; Kajita, M. M., M.; Nagai, T.; Peppas, N. A. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci., 1999, 88, 933-937.